Sheila Mikhail

Sheila Mikhail has over 20 years of biopharmaceutical leadership experience and currently serves as chief executive officer and co-founder of AskBio, a company she started in 2001. Prior to her current role, she served as chief executive officer and co-founder of Bamboo Therapeutics, where, under her direction, the company raised $50 million, advanced a therapeutic for giant axonal neuropathy, a rare genetic disorder, into the clinic, completed pre-IND studies for a Duchenne muscular dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by Pfizer in August 2016 in a deal valued at $827 million. Prior to that, she was part of the management team at Chatham Therapeutics, which was acquired by Baxter in 2014. Ms. Mikhail practiced law for more than 15 years, during which time she founded Life Sciences Law, which serviced clients including Bayer, Gilead, GlaxoSmith Kline, Sanofi and Aventis. She also practiced with Ropes and Gray in Boston. Ms. Mikhail holds a J.D. from Northwestern University, an MBA from the University of Chicago and a B.S. from the University of Illinois at Urbana-Champaign.